Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB01
- Development stage
- Unknown
- Lead developer
- Zhuhai Tengbai Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TB01 is a recombinant chimeric monoclonal antibody developed by Zhuhai Tengbai Pharmaceutical as a biosimilar to cetuximab. It targets the epidermal growth factor receptor (EGFR), a transmembrane glycoprotein that is overexpressed in various solid tumors, including colorectal cancer. By binding to the extracellular domain of EGFR, TB01 competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, thereby blocking the MAPK, PI3K/Akt, and JAK/STAT signaling pathways. This inhibition leads to reduced cell proliferation, induction of apoptosis, and decreased production of angiogenic factors. Additionally, as a chimeric IgG1 antibody, it may mediate antibody-dependent cellular cytotoxicity (ADCC) against tumor cells. TB01 is currently in Phase 3 clinical development for the treatment of metastatic colorectal cancer in patients with RAS wild-type tumors.
- Other names
- recombinant chimeric anti-EGFR monoclonal antibodyTBP01TBP-01TBP 01TB-01TB01TB 01
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on TB01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TB01.